

Pfizer Launches 2014 Integrated Annual Review

Thursday, April 16, 2015 - 04:30am

Pfizer Inc. (NYSE:PFE) addresses some challenging questions often posed by shareholders and the public in its latest integrated [annual review](#) for 2014. In a series of video Q&As, Pfizer colleagues respond to questions such as: “Why do people say medicines are so expensive?” and “Why is it so difficult to find a cure for cancer?”

The 2014 integrated report also highlights a number of partnerships focused on collaborative research and development, how Pfizer is tackling the rise in non-communicable diseases, and access to medicines in low- and middle-income countries. Healthy and active aging also figures prominently in the annual review, reflecting the rapid shift in global demographics.

Ian C. Read, Pfizer chairman and chief executive officer, writes in his annual letter to shareholders included in the annual review that Pfizer “is on a multi-year journey, and during 2014 we achieved a number of important milestones despite a slow-growth global economy and the losses of exclusivity and co-promotion rights to some of our major medicines. We are concentrating our efforts on seeking to profitably grow our business and expanding our sources of revenue, strengthening our core businesses, and bringing forth new therapies that significantly improve peoples' lives.”

Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Everyday, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com.

DISCLOSURE NOTICE: *The information contained in this release is as of April 16, 2015. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.*

This release contains forward-looking information that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. A description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the SEC and available at www.sec.gov and www.pfizer.com.

Media Relations Andrew Topen, 212-733-1338 or Investor Relations Ryan Crowe, 212-733-8160